2. 您的位置
3. 首页
4. 会议论文
5. Mifepristone Derivative FZU-00,003 Suppresses Triplenegative Breast Cancer Cell Growth partially via

Mifepristone Derivative FZU-00,003 Suppresses Triplenegative Breast Cancer Cell Growth partially via

来源 :2019中国肿瘤学大会 | 被引量 : 0次 | 上传用户：GalaxyJW

【摘 要】

：

Objective Triple-negative breast cancer(TNBC)is one of the most malignant breast cancers lacking targeted therapeutics currently due to the heterogeneity of the disease,the absence of well-defined mol

【作 者】

：

RONG LIU CESHI CHEN 

【机 构】

：

Kunming Institute of Zoology,Chinese Academy of Sciences

【出 处】

：

2019中国肿瘤学大会

【发表日期】

：

2019年7期

【关键词】

：

FZU-00 003 KLF5 breast cancer MIF derivatives 

下载到本地 , 更方便阅读

下载此文 赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

　　Objective Triple-negative breast cancer(TNBC)is one of the most malignant breast cancers lacking targeted therapeutics currently due to the heterogeneity of the disease,the absence of well-defined molecular targets and effective targeted therapies.

其他文献

5-FU-induced up-regulation of exosomal PD-L1 reflects immunosuppression in gastric cancer patients a

Objective Although 5-Fluorouracil(5-FU),an important clinical cytotoxic chemotherapy drug,has been thought to directly kill cancer cells through inhibiting DNA and RNA synthesis and even play an immun

会议

exosomal PD-L15-Fluorouracilgastric cancerNivolumab

Sensitization of the efficiency of immunotherapy in HCC by polyIC-triggered CXCL10 secretion in live

Objective Nowadays,the immune checkpoint blockades(ICBs)have been widely used in various kinds of tumors and its also such a hot spot in the research area.

会议

Hepatocellular carcinomaImmune checkpoint blockadePolyinosinicpolycytidylic ac

WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin sign

会议

matrine derivativehepatocellular carcinomacancer stem-like cellsGSK3βAKT

Synergistic effect and Mechanism of E3330 Combination with Vemurafenib in the Treatment of Papillary

会议

BRAF MutationinhibitorvemurafenibE3330synergyPTC

BI2536联合Stattic通过MYC治疗胶质母细胞瘤的实验研究

目的 本研究旨在研究PLK1 抑制剂BI2536 联合STAT3 抑制剂Stattic 通过MYC 诱导胶质瘤细胞凋亡的分子机制，为靶向PLK1 联合STAT3 治疗胶质瘤提供科学依据。

会议

PLK1STAT3MYC胶质瘤

Apatinib inhibits cell proliferation and induces autophagy via the PI3K/Akt signaling pathway in hum

Objective Objective: PTC is the most common type of thyroid cancer and has a favorable prognosis.However,patients with metastatic radioiodine-refractory papillary thyroid carcinoma(PTC)have limited op

会议

Apatinibpapillary thyroid carcinomaapoptosisautophagy

Saracatinib抑制EGFRvⅢ阳性胶质瘤干细胞“干性”特征的实验研究

目的 EGFRvⅢ 是胶质母细胞瘤中最常见的突变，具有促进胶质母细胞瘤进展的多种活性。本研究旨在通过体内、外实验揭示SRC 家族激酶抑制剂Saracatinib 对EGFRvⅢ 阳性胶质瘤干细胞的抑制作用。

会议

EGFRvⅢSaracatinib胶质瘤干细胞SRC

PAK1小分子抑制剂AK963抑制人胃癌细胞增殖迁移及机制研究

目的 胃癌是我国最常见的恶性肿瘤,在我国其发病率和死亡率居各类肿瘤的首位,因此,寻找胃癌的治疗靶点是当前肿瘤研究领域的热点.P21 活化蛋白激酶1(p21-activated kinase 1,PAK1)作为I 类PAK 家族的代表,是进化上保守的丝氨酸/苏氨酸蛋白激酶,在肿瘤细胞信号转导过程中具有枢纽作用,因此已成为有效的肿瘤治疗靶点.但目前针对该靶点抑制剂的研究正处于起步阶段.

会议

P21活化激酶1抑制剂胃癌增殖迁移

Nek2B activates the wnt pathway and promotes triplenegative breast cancer chemotherapy-resistance by

Objective The molecular mechanism of chemotherapy-resistance in triple-negative breast cancer(TNBC)is unclear.Centrosomal kinase Nek2B is the only Nek2 isomer through the whole process of mitosis.Our

会议

β-cateninWnt signaling pathwayTriple-negative breast cancerChemotherapy resis

靶向vegf/vegfr2基因siRNA对小鼠B16F10移植瘤生长的影响

目的 血管内皮生长因子(vascular endothelial growth factor,VEGF)是目前已知的最重要的血管生成调节因子,VEGF 与其受体(vascular endothelial growth factor receptor,VEGFR)特异性结合,调节着血管及肿瘤血管的生成。本研究靶向vegf 及其受体vegfr2 基因 siRNA 对小鼠黑色素瘤细胞B16F10 移植瘤

会议

血管内皮生长因子血管内皮生长因子受体2RNA干扰B16F10移植瘤